Evofem Biosciences, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $(5,465) | $956 |
| Adjustments to reconcile net income (loss) to net cash and cash equivalents and net restricted cash and cash equivalents provided by operating activities: | ||
| Change in fair value of financial instruments | 162 | (1,221) |
| Inventory write-down for excess & obsolescence | 192 | 178 |
| Loss on contingent liability | 58 | 25 |
| Stock-based compensation | 15 | 70 |
| Depreciation | 4 | 6 |
| Amortization of intangible asset | 75 | 223 |
| Noncash interest expense | 614 | 577 |
| Noncash right-of-use asset amortization | 32 | 37 |
| Net loss on disposal or impairment of property and equipment | - | 17 |
| Gain on accounts payable and accrued expenses settlements | - | (5,607) |
| Changes in operating assets and liabilities: | ||
| Trade accounts receivable | 11,920 | 8,683 |
| Inventories | (761) | (864) |
| Prepaid and other assets | (130) | 107 |
| Accounts payable | (1,605) | (1,776) |
| Accrued expenses and other liabilities | (1,636) | 34 |
| Accrued compensation | (1,092) | (849) |
| Contingent liabilities | (50) | - |
| Operating lease liabilities | (32) | (36) |
| Net cash and cash equivalents and net restricted cash and cash equivalents provided by operating activities | 2,301 | 560 |
| Cash flows from investing activities: | ||
| Payments related to intangible asset acquisition | - | (57) |
| Purchases of property and equipment | (2) | - |
| Net cash and cash equivalents and net restricted cash and cash equivalents used in investing activities | (2) | (57) |
| Cash flows from financing activities: | ||
| Payments under short term debt and Notes – carried at fair value | (498) | (135) |
| Net cash and cash equivalents and net restricted cash and cash equivalents used in financing activities | (498) | (135) |
| Net change in cash and cash equivalents and net restricted cash and cash equivalents | 1,801 | 368 |
| Cash and cash equivalents and restricted cash and cash equivalents beginning of period | 578 | 741 |
| Cash, cash equivalents and restricted cash and cash equivalents end of period | $2,379 | $1,109 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Net decrease in contingent liabilities | $3,495 | $2,887 |
| Series E-1 Shares and Series G-1 Shares deemed dividends | 20 | 3 |
| Issuance of Common Stock upon conversion of Series G-1 Shares | 1 | - |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.